Skip to content
Shuttingdown

Theravance Biopharma, Inc.

Pharmaceutical Preparations · GEORGE TOWN, GRAND CAYMAN · CA

No longer listed

High confidence (85%)

Updated Oct 20, 2026, 12:04 AM

What is happening

Derived by rule set status-rules-2026.09.7

The company deregistered its securities and stopped filing with the SEC. Companies do that when they are acquired, when they go private, and when they fail; the filing does not say which.

Latest material event: Theravance Biopharma, Inc. deregistered its securities (Oct 5, 2026)

Timeline

Every material event, newest first. History is never overwritten.

  1. Theravance Biopharma, Inc. deregistered its securities

    Oct 5, 2026

    Registration withdrawn

    • SEC EDGAR — “15-12G 1 tm2626922d1_1512g.htm 15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36033 Theravance Biopharma, Inc. (Exact name of registrant as specified in its charter) c/o Theravance Biopharma US, LLC. 901 Gateway Boulevard South San Francisco, California 94080 (650) 808-6000 (Address, including zip code, and tel…”

  2. Theravance Biopharma, Inc. received a delisting notice from its exchange

    Sep 23, 2026

    Delisting notice received

    • SEC EDGAR — “Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing The information provided in Item 2.01 of this Current Report on Form 8-K is incorporated herein by reference. On September 23, 2026, the Company notified the Nasdaq Stock Market LLC ( Nasdaq ) of the Closing and requested that Nasdaq suspend trading of the Ordinary Shares as of the close of business on September 23, 2026 and file with the U.S. Securities and Exchange Commission (the SEC ) a notification of removal from listing and registration on Form 25 to effect the delisting of the…”

  3. Theravance Biopharma, Inc. was delisted from its exchange

    Sep 23, 2026

    Delisting effective

    • SEC EDGAR — “X0203 0001354457 Nasdaq Stock Market LLC 0001583107 Theravance Biopharma, Inc. 001-36033 901 Gateway Boulevard South San Francisco CA CALIFORNIA 94080 6508083785 Ordinary Shares 17 CFR 240.12d2-2(a)(3) Jennifer Fainer CDO Analyst 2026-09-23”

Company information

Founded
—
Employees (estimate)
—
Industry
Pharmaceutical Preparations
Subindustry
—
Listing
SEC lists the ticker TBPH on Nasdaq.
SEC CIK
0001583107
Website
—
LinkedIn
—
Headquarters
GEORGE TOWN, GRAND CAYMAN, CA
Also known as
—
Legal entities
Theravance Biopharma, Inc.

Sources

Every material source used to build this profile.

  • SEC EDGAR (TIER 1 · UNVERIFIED)

    15-12G 1 tm2626922d1_1512g.htm 15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36033 Theravance Biopharma, Inc. (Exact name of registrant as specified in its charter) c/o Theravance Biopharma US, LLC. 901 Gateway Boulevard South San Francisco, California 94080 (650) 808-6000 (Address, including zip code, and tel…
    View source record

  • SEC Company Submissions (TIER 1 · UNVERIFIED)

    Theravance Biopharma, Inc. — Pharmaceutical Preparations (SIC 2834) — GEORGE TOWN, GRAND CAYMAN, CA
    View source record

  • SEC EDGAR (TIER 1 · UNVERIFIED)

    Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing The information provided in Item 2.01 of this Current Report on Form 8-K is incorporated herein by reference. On September 23, 2026, the Company notified the Nasdaq Stock Market LLC ( Nasdaq ) of the Closing and requested that Nasdaq suspend trading of the Ordinary Shares as of the close of business on September 23, 2026 and file with the U.S. Securities and Exchange Commission (the SEC ) a notification of removal from listing and registration on Form 25 to effect the delisting of the…
    View source record

  • SEC EDGAR (TIER 1 · UNVERIFIED)

    X0203 0001354457 Nasdaq Stock Market LLC 0001583107 Theravance Biopharma, Inc. 001-36033 901 Gateway Boulevard South San Francisco CA CALIFORNIA 94080 6508083785 Ordinary Shares 17 CFR 240.12d2-2(a)(3) Jennifer Fainer CDO Analyst 2026-09-23
    View source record

Status history

Every derived status, with the rule that produced it.

  • NO_LONGER_LISTED → NO_LONGER_LISTEDPUBLIC_LISTING_ENDED · Oct 11, 2026, 12:08 AM

    The company deregistered its securities and stopped filing with the SEC. Companies do that when they are acquired, when they go private, and when they fail; the filing does not say which.

  • UNKNOWN → NO_LONGER_LISTEDPUBLIC_LISTING_ENDED · Sep 27, 2026, 12:10 AM

    The company stopped being publicly listed. A listing ends on the close of a merger as surely as it ends in failure, and the filing does not say which happened here.